secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019262
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt
----------------------------------------------------------------------

- Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.
- Cash, cash equivalents, and restricted cash total $8.8M as of March 31, 2024.
- Company states cash not sufficient for 12 months, raising substantial doubt about going concern.
- Juvenescence line of credit increased by $2.4M in March and $525k in May; total owed $10.4M.
- Lead candidate SER-252 IND submission planned for 2025; Dr. Simba Gill appointed Executive Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer